Posted by Michael Wonder on 29 May 2026
FDA approves label expansion, cementing Tremfya as the only IL‑23 inhibitor proven to help stop further joint damage
28 May 2026 - Johnson & Johnson announced today that the US FDA has approved a supplemental biologics license application to include evidence in the Tremfya (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis.
The inclusion of this key outcome reflects that Tremfya is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with psoriatic arthritis active a first-line treatment option that provides effective symptom control and no new safety signals, while significantly inhibiting irreversible joint damage.
